🇬🇧 Daurismo in United Kingdom

NICE has issued 1 UK HTA decision

Health technology assessment

1 decision from NICE for Daurismo in United Kingdom.

NICE TA646 — — Appraisal terminated

  • Indication assessed: untreated acute myeloid leukaemia (terminated appraisal)

NICE made a decision to terminate the appraisal of Daurismo for the treatment of untreated acute myeloid leukaemia. This decision means that NICE will not be making a recommendation on the use of Daurismo for this indication. The cost-effectiveness of Daurismo was not assessed as part of this decision.

Read official decision →

Daurismo in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United Kingdom

Frequently asked questions

Is Daurismo approved in United Kingdom?

Daurismo does not currently have UK marketing authorisation in our dataset.

Who is the marketing authorisation holder for Daurismo in United Kingdom?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

Has Daurismo been assessed by UK health technology agencies?

Yes — 1 UK HTA decision on record from NICE.